8-KLeadership ChangesExhibits & Filings

DEXCOM INC 8-K Report, Executive Changes (Mar 13, 2017)

Filed March 13, 2017For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K on March 13, 2017, reporting two key events. Firstly, the appointment of Richard Collins to its Board of Directors as a Class III director, effective March 9, 2017. Mr. Collins has also been appointed to the Audit Committee and will receive restricted stock unit grants reflecting his compensation as a non-employee director. This appointment enhances the board's independence and oversight capabilities. Secondly, the company announced the approval of its 2017 Bonus Plan for management and select employees. This plan outlines bonus targets based on achievement of specified financial and performance metrics, including revenue/patient additions, operating expenses, income goals, and corporate milestones. The structure of the bonus plan emphasizes revenue growth and operational efficiency, aiming to incentivize key personnel towards achieving critical business objectives for fiscal year 2017.

Key Highlights

  • 1Richard Collins appointed as a Class III director to the Board of Directors, effective March 9, 2017.
  • 2Richard Collins appointed as a member of the Audit Committee.
  • 3Richard Collins will receive restricted stock unit grants as compensation, with vesting and acceleration clauses typical for directors.
  • 4The company approved a 2017 Bonus Plan for management and select employees.
  • 5The 2017 Bonus Plan links cash bonuses to the achievement of specified financial and performance targets.
  • 6Bonus payouts are weighted towards revenue/patient additions (60%), operating results (20%), and performance milestones (20%).
  • 7The bonus plan includes minimum thresholds for payout and potential 'stretch' performance milestones for increased awards.

Frequently Asked Questions

Richard Collins was appointed as a Class III director to DexCom's Board of Directors, effective March 9, 2017. He has also been appointed to serve on the Audit Committee. His appointment is intended to fill a vacancy and he is considered an independent director.

Richard Collins will be compensated with restricted stock units. He is set to receive a prorated grant for the period from his appointment to June 1, 2017, and a full annual retainer grant on June 1, 2017, provided he is re-elected at the 2017 Annual Meeting. These grants vest after twelve months and accelerate upon a change of control.

The 2017 Bonus Plan is based on achieving targeted annual revenue or new patient addition goals, targeted operating expense and income goals, and corporate performance milestones. Revenue/patient additions account for 60% of the bonus, operating results for 20%, and performance milestones for 20%.

Yes, no portion of the Revenue/Patient Component will be paid unless DexCom meets a specified minimum annual revenue or new patient addition target. Similarly, no portion of the Operating Results Component will be paid unless DexCom meets a specified operating expense target. The plan also includes provisions for increased payouts based on exceeding targets and achieving additional 'stretch' performance milestones.